Ignite Creation Date:
2024-05-05 @ 4:46 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00319254
Status:
COMPLETED
Last Update Posted:
2013-01-31
First Post:
2006-04-24
Brief Title:
Study Evaluating SKI-606 Bosutinib In Subjects With Breast Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase II Study Of SKI-606 In Subjects With Advanced Or Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if SKI-606 Bosutinib is effective in the treatment of advanced or metastatic breast cancer Patients must have current Stage IIIB IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B1871014 | None | None | None |